JPMorgan views the 9% selloff in shares of Novo Nordisk (NVO) after the failure of semaglutide in Alzheimer’s as an overreaction. While the news removes a potential upside share driver, there is limited to no impact on Novo forecasts, the analyst tells investors in a research note. JPMorgan keeps an Overweight rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk shares drop 10% after Alzheimer’s drug trial misses key target
- Novo Nordisk Stock (NVO) Under Pressure as Rival Eli Lilly Joins the $1 Trillion Club
- Mondelez price target lowered to $62 from $63 at Piper Sandler
- PepsiCo price target lowered to $161 from $162 at Piper Sandler
- Boston Beer price target lowered to $220 from $230 at Piper Sandler